In silico design of small peptide-based Hsp90 inhibitor: A novel anticancer agent

Medical Hypotheses

Volumn 81, Issue 5, 2013, Pages 853-861

  Gupta, Uday Kumar ^a   Mahanta, Sailendra ^a   Paul, Subhankar ^a  

^a NATIONAL INSTITUTE OF TECHNOLOGY   (India)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CHAPERONE; HEAT SHOCK PROTEIN 40; HEAT SHOCK PROTEIN 70; HEAT SHOCK PROTEIN 90; HEAT SHOCK PROTEIN 90 ALPHA; HEAT SHOCK PROTEIN 90 INHIBITOR; HSP ORGANIZING PROTEIN; ISOLEUCYLASPARAGINYLSERYLALALNYLTYROSYLLYSYLLEUCYLLYSYLTYROSYLANALYLARGINYLGLYCINE; MUTANT PROTEIN; PROTEIN; PROTEIN P53; UNCLASSIFIED DRUG;

AMINO ACID SEQUENCE; ARTICLE; BINDING AFFINITY; COMPLEX FORMATION; COMPUTER MODEL; COMPUTER PROGRAM; DRUG DESIGN; DRUG PROTEIN BINDING; DRUG SOLUBILITY; ISOELECTRIC POINT; MOLECULAR DOCKING; MOLECULAR MODEL; MOLECULAR WEIGHT; PROTEIN MODIFICATION; WILD TYPE;

AMINO ACID SEQUENCE; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; COMPUTER SIMULATION; DRUG DESIGN; FEMALE; HOMEODOMAIN PROTEINS; HSP90 HEAT-SHOCK PROTEINS; HUMANS; MOLECULAR SEQUENCE DATA; PEPTIDES; TUMOR SUPPRESSOR PROTEINS;

EID: 84886789034     PISSN: 03069877     EISSN: 15322777     Source Type: Journal    
DOI: 10.1016/j.mehy.2013.08.006     Document Type: Article

References (30)

1. Hartl F.U. Molecular chaperones in cellular protein folding. Nature 1996, 381:571-579.
2. Sherman M.Y., Goldberg A.L. Cellular defenses against unfolded proteins: a cell biologist thinks about neurodegenerative diseases. Neuron 2001, 29:15-32.
3. Becker J., Craig E.A. Heat-shock proteins as molecular chaperones. Eur J Biochem 1994, 219:11-23.
4. Morimoto R.I., Kline M.P., Bimston D.N., Cotto J.J. The heat-shock response: regulation and function of heat-shock proteins and molecular chaperones. Essays Biochem 1997, 32:17-29.
5. Picard D. Heat-shock protein 90, a chaperone for folding and regulation. Cell Mol Life Sci CMLS 2002, 59:1640-1648.
6. Soti C., Nagy E., Giricz Z., Vígh L., Csermely P., Ferdinandy P. Heat shock proteins as emerging therapeutic targets. Br J Pharmacol 2005, 146:769-780.
7. Millson S.H., Truman A.W., Racz A., Hu B., Panaretou B., Nuttall J., et al. Expressed as the sole Hsp90 of yeast, the alpha and beta isoforms of human Hsp90 differ with regard to their capacities for activation of certain client proteins, whereas only Hsp90beta generates sensitivity to the Hsp90 inhibitor radicicol. FEBS J 2007, 274:4453-4463.
8. Cooper L.C., Prinsloo E., Edkins A.L., Blatch G.L. Hsp90alpha/beta associates with the GSK3beta/axin1/phospho-beta-catenin complex in the human MCF-7 epithelial breast cancer model. Biochem Biophys Res Commun 2011, 413:550-554.
9. Whitesell L., Lindquist S.L. HSP90 and the chaperoning of cancer. Nat Rev Cancer 2005, 5:761-772.
10. Neckers L., Neckers K. Heat-shock protein 90 inhibitors as novel cancer chemotherapeutic agents. Expert Opin Emerging Drugs 2002, 7:277-288.
11. Kamal A., Boehm M.F., Burrows F.J. Therapeutic and diagnostic implications of Hsp90 activation. Trends Mol Med 2004, 10:283-290.
12. Powers M.V., Workman P. Targeting of multiple signalling pathways by heat shock protein 90 molecular chaperone inhibitors. Endocr Relat Cancer 2006, 13(Suppl. 1):S125-S135.
13. Beliakoff J., Whitesell L. Hsp90: an emerging target for breast cancer therapy. Anticancer Drugs 2004, 15:651-662.
14. Csermely P., Schnaider T., Soti C., ProhÃszka Z., Nardai G. The 90kDa molecular chaperone family: structure, function, and clinical applications. A comprehensive review. Pharmacol Ther 1998, 79:129-168.
15. Pimienta G., Herbert K.M., Regan L. A compound that inhibits the HOP-Hsp90 complex formation and has unique killing effects in breast cancer cell lines. Mol Pharm 2011, 8:2252-2261.
16. Onuoha S.C., Coulstock E.T., Grossmann J.G., Jackson S.E. Structural studies on the co-chaperone Hop and its complexes with Hsp90. J Mol Biol 2008, 379:732-744.
17. Southworth Daniel R., Agard David A. Client-loading conformation of the Hsp90 molecular chaperone revealed in the cryo-EM structure of the human Hsp90/Hop complex. Mol Cell 2011, 42:771-781.
18. Kelley L.A., Sternberg M.J.E. Protein structure prediction on the web: a case study using the Phyre server. Nat Protoc 2009, 4:363-371.
19. Ritchie D.W. Recent progress and future directions in protein-protein docking. Curr Protein Pept Sci 2008, 9:1-15.
20. +: multiple ligand-protein interaction diagrams for drug discovery. J Chem Inf Model 2011, 51:2778-2786.
21. Maupetit J., Derreumaux P., Tuffery P. A fast and accurate method for large-scale de novo peptide structure prediction. J Comput Chem 2009.
22. Maupetit J., Derreumaux P., Tuffery P. PEP-FOLD: an online resource for de novo peptide structure prediction. Nucleic Acids Res 2009, 37:498-503.
23. Maupetit J., Tuffery P., Derreumaux P. A coarse-grained protein force field for folding and structure prediction. Proteins 2007, 69:394-408.
24. Pace C.N., Scholtz J.M. A helix propensity scale based on experimental studies of peptides and proteins. Biophys J 1998, 75:422-427.
25. Chiosis G., Neckers L. Tumor selectivity of Hsp90 inhibitors: the explanation remains elusive. ACS Chem Biol 2006, 1:279-284.
26. Kamal A., Thao L., Sensintaffar J., Zhang L., Boehm M.F., Fritz L.C., et al. A high-affinity conformation of Hsp90 confers tumour selectivity on Hsp90 inhibitors. Nature 2003, 425:407-410.
27. Wong C., Chen S. Heat shock protein 90 inhibitors: new mode of therapy to overcome endocrine resistance. Cancer Res 2009, 69:8670-8677.
28. Egorin M.J., Rosen D.M., Wolff J.H., Callery P.S., Musser S.M., Eiseman J.L. Metabolism of 17-(allylamino)-17-demethoxygeldanamycin (NSC 330507) by murine and human hepatic preparations. Cancer Res 1998, 58:2385-2396.
29. Glaze E., Lambert A., Smith A., Page J., Johnson W., McCormick D., et al. Preclinical toxicity of a geldanamycin analog, 17-(dimethylaminoethylamino)-17-demethoxygeldanamycin (17-DMAG), in rats and dogs: potential clinical relevance. Cancer Chemother Pharmacol 2005, 56:637-647.
30. Plescia J., Salz W., Xia F., Pennati M., Zaffaroni N., Daidone M.G., et al. Rational design of shepherdin, a novel anticancer agent. Cancer Cell 2005, 7:457-468.